The dual applicability of CD155 CAR-T cells to both AML and solid tumors could be particularly valuable for patients with secondary malignancies induced as the result of chemotherapy or radiotherapy of a primary tumor, or in patients with certain germline mutations such as BRCA1 or BRCA2 that lead to susceptibility to more than 1 type of cancer, sometimes occurring concurrently. Here, BRCA1 is linked to acute myeloid leukemia.